ReviewJournal of the peripheral nervous system : JPNS2013
Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies.
Review in Journal of the peripheral nervous system : JPNS, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Population Pharmacokinetics and Pharmacodynamics of Immunoglobulins: A Systematic Review.Clinical pharmacokinetics · 2026Pooled it
- Analysis of relapse by inflammatory Rasch-built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy.Journal of the peripheral nervous system : JPNS · 2022Trial
- Autoantibodies in COVID-19: implications for disease severity and clinical outcomes.Frontiers in immunology · 2024Review
- Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: A Historical Perspective.Journal of clinical medicine · 2023Review
- How I Treat Chronic Inflammatory Demyelinating Polyneuropathy Podcast.Neurology and therapy · 2023Article
- Pediatric multisystem inflammatory syndrome associated with COVID-19: Insights in pathogenesis and clinical management.World journal of virology · 2023Review
- Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy.CPT: pharmacometrics & systems pharmacology · 2021Article
- Individualizing Therapy in CIDP: A Mini-Review Comparing the Pharmacokinetics of Ig With SCIg and IVIg.Frontiers in neurology · 2021Review
- Prognostic value of neurofilament light chain in chronic inflammatory demyelinating polyneuropathy.Brain communications · 2021Article
- VNTR2/VNTR3 genotype in theTherapeutic advances in neurological disorders · 2021Article
- Long-term human IgG treatment improves heart and muscle function in a mouse model of Duchenne muscular dystrophy.Journal of cachexia, sarcopenia and muscle · 2020Article
- Immune Globulin Subcutaneous (Human) 20% (HizentraCNS drugs · 2019Review
- Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy.Biomarker research · 2019Review
- Individualized immunoglobulin therapy in chronic immune-mediated peripheral neuropathies.Journal of the peripheral nervous system : JPNS · 2018Review
- Recombinant IgG1 Fc hexamers block cytotoxicity and pathological changes in experimental in vitro and rat models of neuromyelitis optica.Neuropharmacology · 2018Article
- Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment.BMJ case reports · 2018Article
- Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy.Scientific reports · 2017Article
- Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications.Nature reviews. Neurology · 2017Review
- Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy.Brain and behavior · 2016Article
- Rescue effects of intravenous immunoglobulin on optic nerve degeneration in a rat model of neuromyelitis optica.Japanese journal of ophthalmology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intravenous immunoglobulin (IVIG) is widely used in autoimmune neuromuscular diseases whose pathogenesis is undefined. Many different effects of IVIG have been demonstrated in vitro, but few studies actually identify the mechanism(s) most important in vivo. Doses and treatment intervals are generally chosen empirically. Recent studies in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy show that some effects of IVIG are readily reversible and highly dependent on the serum IgG level. This suggests that in some autoantibody-mediated neuromuscular diseases, IVIG directly competes with autoantibodies that reversibly interfere with nerve conduction. Mechanisms of action of IVIG which most likely involve direct competition with autoantibodies include: neutralization of autoantibodies by anti-idiotypes, inhibition of complement deposition, and increasing catabolism of pathologic antibodies by saturating FcRn. Indirect immunomodulatory effects are not as likely to involve competition and may not have the same reversibility and dose-dependency. Pharmacodynamic analyses should be informative regarding most relevant mechanism(s) of action of IVIG as well as the role of autoantibodies in the immunopathogenesis of each disease. Better understanding of the role of autoantibodies and of the target(s) of IVIG could lead to more efficient use of this therapy and better patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.